Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Aclaris Therapeutics (ACRS) over the last 8 years, with Q2 2025 value amounting to -$56000.0.

  • Aclaris Therapeutics' Change in Receivables fell 1666.67% to -$56000.0 in Q2 2025 from the same period last year, while for Jun 2025 it was -$131000.0, marking a year-over-year decrease of 2358.49%. This contributed to the annual value of $20000.0 for FY2024, which is 11075.27% up from last year.
  • Aclaris Therapeutics' Change in Receivables amounted to -$56000.0 in Q2 2025, which was down 1666.67% from -$68000.0 recorded in Q1 2025.
  • Aclaris Therapeutics' Change in Receivables' 5-year high stood at $202000.0 during Q1 2023, with a 5-year trough of -$255000.0 in Q2 2023.
  • Over the past 5 years, Aclaris Therapeutics' median Change in Receivables value was -$44000.0 (recorded in 2022), while the average stood at -$32111.1.
  • Data for Aclaris Therapeutics' Change in Receivables shows a peak YoY increase of 192000.0% (in 2023) and a maximum YoY decrease of 647500.0% (in 2023) over the last 5 years.
  • Quarter analysis of 5 years shows Aclaris Therapeutics' Change in Receivables stood at -$188000.0 in 2021, then skyrocketed by 39.89% to -$113000.0 in 2022, then soared by 57.52% to -$48000.0 in 2023, then skyrocketed by 47.92% to -$25000.0 in 2024, then crashed by 124.0% to -$56000.0 in 2025.
  • Its Change in Receivables was -$56000.0 in Q2 2025, compared to -$68000.0 in Q1 2025 and -$25000.0 in Q4 2024.